Literature DB >> 6361169

Immunofluorescence and immunoelectron microscopic studies in cicatricial pemphigoid.

J D Fine, G R Neises, S I Katz.   

Abstract

We have studied various tissues from 10 patients with cicatricial pemphigoid using direct and indirect immunofluorescence, mechanical suction blister induction, and immunoelectron microscopy. In 8 of the 10 patients, direct immunofluorescence of buccal mucosa showed a linear deposition of immunoreactants, IgG and C3 being those most commonly detected. Direct immunofluorescence of skin was positive in only 4 patients. Only 1 patient had a detectable circulating anti-basement membrane zone antibody. Substitution of normal human oral mucosa for adult skin as the tissue substrate for indirect immunofluorescence did not prove useful in the detection of circulating autoantibodies. Immunoelectron microscopy was performed in the skin or mucosa (buccal or ocular) of 6 patients, revealing lamina lucida localization of in vivo-bound immunoreactants. Indirect immunofluorescence studies on mechanically induced suction blisters in skin of 2 patients with in vivo-bound IgG suggest that the lamina lucida antigen involved in cicatricial pemphigoid may be distinct from the bullous pemphigoid antigen.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6361169     DOI: 10.1111/1523-1747.ep12259075

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  10 in total

1.  Obstructive respiratory failure in cicatricial pemphigoid.

Authors:  C R de Carvalho; M B Amato; L M Da Silva; C S Barbas; R A Kairalla; P H Saldiva
Journal:  Thorax       Date:  1989-07       Impact factor: 9.139

2.  Disseminated cicatricial pemphigoid in a child and in an adult. Ultrastructural diagnostic criteria and differential diagnosis with special reference to acquired epidermolysis bullosa.

Authors:  I Hausser; M Fartasch; E Schleiermacher; I Anton-Lamprecht
Journal:  Arch Dermatol Res       Date:  1987       Impact factor: 3.017

Review 3.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

4.  Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease.

Authors:  N Domloge-Hultsch; W R Gammon; R A Briggaman; S G Gil; W G Carter; K B Yancey
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

5.  Ultrastructural localization of binding sites of sera from patients with linear IgA bullous dermatosis.

Authors:  C Kowalewski; M Haftek; S Jablonska; D Schmitt
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

6.  Conjunctival involvement in cicatricial and bullous pemphigoid: a clinical and immunopathological study.

Authors:  P A Frith; V A Venning; F Wojnarowska; P R Millard; A J Bron
Journal:  Br J Ophthalmol       Date:  1989-01       Impact factor: 4.638

Review 7.  Recent advances on the 180-kDa epidermal antigen in autoimmune subepidermal bullous skin diseases.

Authors:  P Bernard
Journal:  Springer Semin Immunopathol       Date:  1992

8.  Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

9.  Treatment strategies in mucous membrane pemphigoid.

Authors:  Ann G Neff; Matthew Turner; Diya F Mutasim
Journal:  Ther Clin Risk Manag       Date:  2008-06       Impact factor: 2.423

10.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.